OTCMKTS:MATN Mateon Therapeutics (MATN) Stock Price, News & Analysis → Bible Shocker: Have You Seen Elon Musk’s Miracle? (From InvestorPlace) (Ad) Free MATN Stock Alerts $0.04 0.00 (0.00%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$0.04▼$0.0450-Day Range$0.03▼$0.0452-Week Range$0.13▼$0.38Volume106,436 shsAverage Volume338,444 shsMarket Capitalization$3.43 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsSEC FilingsStock AnalysisChartFinancialsSEC Filings Get Mateon Therapeutics alerts: Email Address Ad InvestorPlaceBible Shocker: Have You Seen Elon Musk’s Miracle?Breaking News: Elon Musk Invents New Type of A.I. (Shocking) Elon Musk is about to shock the world again with this new type of A.I.… Minting new millionaires in the process.Click here for the full story… About Mateon Therapeutics Stock (OTCMKTS:MATN)Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.Read More MATN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MATN Stock News HeadlinesFebruary 27, 2024 | wsj.comViking Therapeutics Inc.February 25, 2023 | benzinga.comSorrento Therapeutics Stock (OTC:SRNEQ), Quotes and News SummarySee More Headlines Receive MATN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mateon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2019Today5/19/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolOTCMKTS:MATN Previous SymbolNASDAQ:MATN CUSIPN/A CIK908259 Webwww.mateon.com Phone650-635-7000FaxN/AEmployees13Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,640,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-64.66% Return on Assets-42.92% Debt Debt-to-Equity RatioN/A Current Ratio0.17 Quick Ratio0.17 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book0.19Miscellaneous Outstanding Shares90,240,000Free FloatN/AMarket Cap$3.43 million OptionableNot Optionable Beta1.33 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Vuong Trieu (Age 58)Chairman & CEO Comp: $166.53kMr. Amit Shah (Age 54)Chief Financial Officer Comp: $66.5kDr. Chulho Park Ph.D. (Age 54)Chief Technology Officer Comp: $129.86kDr. Larn Hwang (Age 58)Chief Scientific Officer Dr. Anthony E. Maida III (Age 69)M.A., M.B.A., MA, MBA, Ph.D., Chief Clinical Officer of Translational Medicine & Director Dr. Seymore Howard Fein (Age 72)Chief Medical Officer Mr. Saranjit SaundCBO & GM of AI DivisionMr. Burcak BeserCTO of AI DivisionMore ExecutivesKey CompetitorsPhaseBio PharmaceuticalsNASDAQ:PHASVirpax PharmaceuticalsNASDAQ:VRPXCyclacel PharmaceuticalsNASDAQ:CYCCTransCode TherapeuticsNASDAQ:RNAZAtrecaNASDAQ:BCELView All Competitors MATN Stock Analysis - Frequently Asked Questions How have MATN shares performed in 2024? Mateon Therapeutics' stock was trading at $0.0383 on January 1st, 2024. Since then, MATN shares have decreased by 0.7% and is now trading at $0.0380. View the best growth stocks for 2024 here. How were Mateon Therapeutics' earnings last quarter? Mateon Therapeutics, Inc. (OTCMKTS:MATN) issued its earnings results on Wednesday, May, 15th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.02). What other stocks do shareholders of Mateon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mateon Therapeutics investors own include Amarin (AMRN), Cyclacel Pharmaceuticals (CYCC), Oramed Pharmaceuticals (ORMP), Synergy Pharmaceuticals (SGYP), VIVUS (VVUS), Idera Pharmaceuticals (IDRA), Ascent Solar Technologies (ASTI), BioDelivery Sciences International (BDSI) and Avid Bioservices (CDMO). How do I buy shares of Mateon Therapeutics? Shares of MATN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:MATN) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingShocking $16T Elon Musk Crypto LeakCrypto 101 MediaForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsDems have chosen Biden replacement?Paradigm PressHow Biden has already won 2024Porter & CompanyExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersA letter is coming from the "Bureau of the Fiscal Service".Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mateon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.